Apolipoprotein E imbalance in the cerebrospinal fluid of Alzheimer’s disease patients

Authors:

Abstract
Objective: The purpose of this study was to examine the levels of cerebrospinal fluid (CSF) apolipoprotein E (apoE) species in Alzheimer’s disease (AD) patients. Methods: We analyzed two CSF cohorts of AD and control individuals expressing different APOE genotypes. Moreover, CSF samples from the TgF344-AD rat model were included. Samples were run in native- and SDS-PAGE under reducing or non-reducing conditions (with or without β-mercaptoethanol). Immunoprecipitation combined with mass spectrometry or western blotting analyses served to assess the identity of apoE complexes. Results: In TgF344-AD rats expressing a unique apoE variant resembling human apoE4, a ~35-kDa apoE monomer was identified, increasing at 16.5 months compared with wild-types. In humans, apoE isoforms form disulfide-linked dimers in CSF, except apoE4, which lacks a cysteine residue. Thus, controls showed a decrease in the apoE dimer/monomer quotient in the APOE ε3/ε4 group compared with ε3/ε3 by native electrophoresis. A major contribution of dimers was found in APOE ε3/ε4 AD cases, and, unexpectedly, dimers were also found in ε4/ε4 AD cases. Under reducing conditions, two apoE monomeric glycoforms at 36 kDa and at 34 kDa were found in all human samples. In AD patients, the amount of the 34-kDa species increased, while the 36-kDa/34-kDa quotient was lower compared with controls. Interestingly, under reducing conditions, a ~100-kDa apoE complex, the identity of which was confirmed by mass spectrometry, also appeared in human AD individuals across all APOE genotypes, suggesting the occurrence of aberrantly resistant apoE aggregates. A second independent cohort of CSF samples validated these results. Conclusion: These results indicate that despite the increase in total apoE content the apoE protein is altered in AD CSF, suggesting that function may be compromised.
Funding Information
  • Conselleria d'Educació, Investigació, Cultura i Esport (ACIF/2019/062, ACIF/2019/062)
  • Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (PI15/00665, PI15/00665, PI15/00665)
  • Fundación Carmen y Severo Ochoa (SEV-2017-0723, SEV-2017-0723, SEV-2017-0723)
  • Ministerio de Ciencia, Innovación y Universidades (PID2019-107738RB-I00, PID2019-107738RB-I00, PID2019-107738RB-I00)
  • Swedish State Support for Clinical Research (ALFGBG-720931, ALFGBG-720931, ALFGBG-720931)
  • Alzheimer's Drug Discovery Foundation (201809-2016862, 201809-2016862, 201809-2016862, RDAPB-201809-2016615)
  • Alzheimer's Association (ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, ZEN-21-848495)
  • Instituto de Salud Carlos III (PI14/01126, PI17/01019, PI20/01473 and INT16/00171, PI18/00435, PI14/1561, PI17/01896 and PI20/1330, PI18/00893)
  • Generalitat de Catalunya (SLT006/17/00125, SLT006/17/00119)
  • National Institutes of Health (1R01AG056850-01A1; R21AG056974 and R01AG061566, 1R01AG068398-01)
  • Departament de Salut, Generalitat de Catalunya (SLT002/16/00408)
  • Vetenskapsrådet (2018-02532, 2017-00915)
  • European Research Council (681712)
  • Stiftelsen för Gamla Tjänarinnor (FO2019-0228)
  • Horizon 2020 Framework Programme (860197)
  • European Union Joint Programme - Neurodegenerative Disease Research (JPND2021-00694)
  • UK Dementia Research Institute (UKDRI-1003)
  • swedish alzheimer foundation (AF-742881)
  • Hjärnfonden (FO2017-0243)
  • VINNOVA (ALFGBG-715986)
  • European Union Joint Program for Neurodegenerative Disorders (JPND2019-466-236)

This publication has 67 references indexed in Scilit: